Machine-learning Algorithm for Prediction of CKD From Retinal Images (healthy route)

November 10, 2026 updated by: Mohamed Khalis, Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)

A Validation Study to Assess Performance Accuracy of a Machine-Learning Algorithm for the Prediction of Chronic Kidney Disease (CKD) From Digital Retinal Images

This is a non-interventional study being conducted to validate the performance of a machine learning algorithm for prediction of eGFR from digital retinal images in a target population for future intended use as a populated-based screening tool. Secondary objectives will include prediction of blood pressure (> or ≤ 140/90 mmHg) and presence or absence of T2DM as determined by glycated haemoglobin (HbA1c >6.5%) or on the basis of clinical history. Once validated, the methodology will be deployed for health screening to improve access to healthcare.

Study Overview

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Mohamed Khalis, Professor
  • Phone Number: +212 628-245023
  • Email: mkhalis@um6ss.ma

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population consists of adult patients diagnosed with chronic kidney disease (CKD), hypertension, diabetes mellitus, or without these conditions, attending routine outpatient clinics at Hôpital Universitaire International Cheikh Khalifa Ibn Zaid in Casablanca and Centre Hospitalier Universitaire Hassan II in Fez, Morocco.

Description

Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Participant must be ≥ 18 years of age, at the time of signing the informed consent.
  2. Previously documented eGFR ≥ 3months
  3. Any participant with a positive dipstick result for proteinuria of at least trace
  4. Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol

Exclusion Criteria:

  • Participants are excluded from the study if any of the following criteria apply:

    1. As judged by the investigator, any evidence of a condition which in the investigator's opinion makes it undesirable for the participant to participate in the study.
    2. Any known eye condition that may preclude clear imaging of the retina for example; cataracts
    3. Individuals with hypertensive emergencies and hyperglycemic or hypoglycemic emergencies
    4. Involvement in the planning and/or conduct of the study (applies to HHA/ AstraZeneca staff and/or staff at the study site).
    5. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: CASE_CONTROL
  • Time Perspectives: CROSS_SECTIONAL

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
CKD Cases

350 participants (cases) with diabetes and/or hypertension and/or CKD with previously documented eGFR < 60 ml/min/1.73m2 ≥3 months

A machine learning-based algorithm analyzes retinal images to assess its ability to detect chronic kidney disease

Controls

150 (controls) with previously documented eGFR ≥ 60 ml/min/1.73m2 ≥ 3 months

A machine learning-based algorithm analyzes retinal images to assess its ability to detect chronic kidney disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The accuracy of a machine-learning based algorithm to predict high risk CKD from digital retinal images
Time Frame: Baseline

To quantify the discrimination of the machine-learning algorithm for identifying the binary target condition of persistent eGFR <60 mL/min/1.73 m², using standard-of-care serum creatinine as the reference standard and the AUROC with a 95% confidence interval as the primary performance measure

Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accuracy of the Machine Learning Algorithm for Detection of Hypertension and T2DM
Time Frame: Baseline

To quantify the sensitivity, specificity, and discriminative performance of a machine-learning-based algorithm for identifying SBP >140 mmHg from digital retinal images, using standard-of-care assessment as the reference standard and the AUROC with a 95% confidence interval as the primary performance measure

Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

October 31, 2027

Study Registration Dates

First Submitted

July 16, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

July 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe